Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
https://www.zacks.com/stock/news/2193809/roche-rhhby-breast-cancer-drug-meets-primary-goal-in-phase-iii?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193809
Dec 05, 2023 - Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.
0
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
https://www.zacks.com/stock/news/2193099/roche-rhhby-to-acquire-obesity-drug-maker-carmot-for-2-7b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193099
Dec 04, 2023 - Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
0
Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes
https://www.fool.com/investing/2023/12/02/why-im-considering-selling-pfizer-for-tax-loss-har/?source=iedfolrf0000001
Dec 02, 2023 - For growth investors, it may be time to sell this pharma stock for tax-loss harvesting purposes.
0
An Important History Lesson for Gene-Editing Investors
https://www.fool.com/investing/2023/12/02/an-important-history-lesson-for-gene-editing-inves/?source=iedfolrf0000001
Dec 02, 2023 - Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.
0